IP Library Granted Patent US 10,568,827
Granted Patent B2
US 10,568,827 · App. 15/756,698 · Granted Feb 25, 2020

External dermal agent for reducing yellowish dullness

Inventors: Masaki Miyake (Okayama, JP); Motoyuki Suzuki (Okayama, JP); Tatsuya Ishihara (Okayama, JP); Toshio Ariyasu (Okayama, JP)
Assignee: HAYASHIBARA CO., LTD.
A61K8/602A61K8/36A61K8/365A61K8/368A61K8/49A61K8/498A61K8/60A61K9/08A61K9/16A61K9/20A61K31/19A61K31/198A61K31/353A61K31/702A61K31/7048A61Q19/00A61Q19/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,568,827
App. No.
15/756,698
Granted
Feb 25, 2020
Kind
B2
Abstract

[Object] The present invention has an object to provide an external dermal agent for reducing skin yellowness already generated in the skin. [Means to Attain the Object] The above object is solved by providing an external dermal agent for reducing skin yellowness already generated in the skin, which contains hesperetin and/or glycosyl hesperetin as an effective ingredient(s).

Claims (8)

1. A method for reducing skin yellowness and carbonyl protein already generated in the skin of a subject in need thereof, which comprises a step of applying an external dermal agent comprising hesperetin and/or glycosyl hesperetin along with one or more members selected from the group consisting of maltose, maltotetraose, glycosyl trehalose, lactic acid, ferulic acid, glucuronic acid, acetic acid, sorbic acid, and sodium glutamate as effective ingredients to the skin of said subject, wherein a ratio of carbonyl protein to no test agent control is measured and is reduced after applying the external dermal agent.

2. The method of claim 1 , wherein said glycosyl hesperetin is one or more members selected from the group consisting of hesperidin, α-glycosyl hesperidin, and 7-O-β-glucosyl hesperetin.

3. The method of claim 2 , wherein said α-glycosyl hesperidin is α-glucosyl hesperidin.

4. The method of claim 1 , wherein said glycosyl hesperetin contains glycosyl hesperetin in an amount of at least 50% by mass but less than 100% by mass, on a dry solid basis.

5. The method of claim 2 , wherein the purity of said α-glycosyl hesperidin in said glycosyl hesperetin is at least 50% by mass but less than 100% by mass, on a dry solid basis.

6. The method of claim 1 , wherein said external dermal agent further comprises one or more other members selected from the group consisting of saccharides, organic acids, and amino acids.

7. The method of claim 1 , wherein said external dermal agent contains said hesperetin and/or said glycosyl hesperetin in a total amount of at least 0.0001% by mass but less than 100% by mass.

8. The method of claim 1 , wherein said external dermal agent is in the form of a tablet, granule, powder, spray, suspension, paste, jelly, or liquid.

Assignments (2)
CHANGE OF NAME Recorded Mar 18, 2025
From: HAYASHIBARA CO., LTD.
To: NAGASE VIITA CO., LTD.
Reel/Frame 070538/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2018
From: MIYAKE, MASAKI; SUZUKI, MOTOYUKI; ISHIHARA, TATSUYA; ARIYASU, TOSHIO
To: HAYASHIBARA CO., LTD.
Reel/Frame 045076/0209 →
Priority Claims (1)
JP 2015-173358 · Sep 2, 2015 · national
Continuity (1)
Related Publication 20180243195A1 · Aug 30, 2018